Literature DB >> 25554102

Drug-induced lupus.

Robert L Rubin1.   

Abstract

INTRODUCTION: Drug-induced lupus (DIL) refers to an idiosyncratic side effect of numerous, apparently unrelated, medications, in which symptoms overlap with those of systemic lupus erythematosus. DIL is reversible by discontinuation of the medication. The etiological mechanism underlying DIL is linked to the inherent susceptibility of the adaptive immune system to lapse into auto-reactivity. AREAS COVERED: Clinical and laboratory features of DIL will be compared with those of idiopathic systemic lupus and with other types of drug reactions with overlapping features. Formerly commonly-used drugs conferred very high risk of developing DIL, although the probability of developing DIL has not been established with most lupus-inducing drugs. Pharmacological or physiochemical properties of the parent compounds are uninformative, but the importance of reactive drug metabolites in initiating autoimmunity will be discussed. As with most systemic autoimmune diseases, the pathogenesis of DIL is complex and obscure. The role of complement and human leukocyte allotypes as well as drug acetylator phenotype inform the underlying mechanism, and several of these non-mutually exclusive concepts will be described. EXPERT OPINION: The pros and cons of proposed mechanisms for DIL will be discussed in the context of current understanding of autoimmunity and immune tolerance to self.

Entities:  

Keywords:  autoantibodies; autoimmune disease; drug metabolism; drug-induced lupus; immune complexes; immune tolerance; pathogenesis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 25554102     DOI: 10.1517/14740338.2015.995089

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  26 in total

Review 1.  Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors:  Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 2.  Drug-induced glomerular disease: attention required!

Authors:  Jai Radhakrishnan; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

Review 3.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

Review 4.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

5.  Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts.

Authors:  Jean C Pfau; Christopher Barbour; Brad Black; Kinta M Serve; Marvin J Fritzler
Journal:  J Toxicol Environ Health A       Date:  2018-09-19

Review 6.  An update on drug-induced arthritis.

Authors:  Marwan H Adwan
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

Review 7.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

8.  Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.

Authors:  Esther Erdei; Chris Shuey; Bernadette Pacheco; Miranda Cajero; Johnnye Lewis; Robert L Rubin
Journal:  J Autoimmun       Date:  2019-03-14       Impact factor: 7.094

9.  Prescription medication use and antinuclear antibodies in the United States, 1999-2004.

Authors:  Gregg E Dinse; Christine G Parks; Helen C S Meier; Caroll A Co; Edward K L Chan; Todd A Jusko; James Yeh; Frederick W Miller
Journal:  J Autoimmun       Date:  2018-05-18       Impact factor: 7.094

10.  Infliximab-induced autoantibodies: a multicenter study.

Authors:  João Luiz Pereira Vaz; Vander Fernandes; Felipe Nogueira; Adriano Arnóbio; Roger A Levy
Journal:  Clin Rheumatol       Date:  2015-12-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.